The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Recent unsuccessful clinical trials have reduced enthusiasm for the development of neuroprotective drugs. Here, we use empirical evidence derived from systematic reviews of stroke drug development to identify stages of drug development which might be improved. We then propose exemplar strategies which may be helpful, along with some basic economic modelling of what the impact of such strategies might be. This suggests that relatively straightforward measures might reduce the costs of drug development by $5·8bn or 31%.

Item Type:	Refereed Article
Keywords:	Neuroprotection; Pharmacoecomonics; Translation
Research Division:	Biomedical and Clinical Sciences
Research Group:	Neurosciences
Research Field:	Neurology and neuromuscular diseases
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Clinical health not elsewhere classified
UTAS Author:	Howells, DW (Professor David Howells)
ID Code:	101072
Year Published:	2012
Web of Science® Times Cited:	35
Deposited By:	Office of the School of Medicine
Deposited On:	2015-06-09
Last Modified:	2017-11-06
Downloads:	0